Skip Navigation


Mol. Hum. Reprod. Advance Access originally published online on August 20, 2008
Molecular Human Reproduction 2008 14(9):513-520; doi:10.1093/molehr/gan048
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
14/9/513    most recent
gan048v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Johnson, B.V.
Right arrow Articles by Keough, R.A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johnson, B.V.
Right arrow Articles by Keough, R.A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Understanding pluripotency—how embryonic stem cells keep their options open

B.V. Johnson1,3, N. Shindo1,4, P.D. Rathjen1,2, J. Rathjen1,2 and R.A. Keough1,5

1School of Molecular and Biomedical Science, The University of Adelaide, South Australia 5005, Australia 2Department of Zoology, University of Melbourne, Melbourne, Victoria 3010, Australia

5 Correspondence address. E-mail: rebecca.keough{at}adelaide.edu.au

Embryonic stem (ES) cells have the capacity to proliferate indefinitely in culture while maintaining the ability to differentiate to form any of the cells of the body. This unique combination of functions suggests that these cells could provide a potentially unlimited source of differentiated cells for the treatment of disease and aging. Understanding the molecular processes that underpin these functions in ES cells will allow us to harness their potential and develop strategies that control their differentiation. Combination of controlled differentiation with ground-breaking technologies for the reversal of somatic cells to an ES cell-like state promise the generation of patient-derived pluripotent cell lines for the treatment of disease in the future.

Key words: pluripotency/embryonic stem cell/early primitive ectoderm-like cell/cell reprogramming

3 Present address: Institute of Medical and Veterinary Science, Adelaide, South Australia 5001, Australia

4 Present address: The Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan

Submitted on June 5, 2008; resubmitted on August 11, 2008; accepted on August 12, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.